Table of Contents
What changed
Operating revenue rose 16.4% to NZ$803.7m, with Homecare growing roughly 25.8% to NZ$314.4m and Hospital growing 11.1% to NZ$487.5m, shifting the product mix 2.9pp toward Homecare. Profit before tax climbed 23.0% to NZ$140.6m, but NPAT grew only 11.9% to NZ$107.3m because the effective tax rate rose to 23.7% from 16.1%. Operating cash flow recovered to NZ$156.5m from a depressed NZ$1.9m in HY23, but capex more than doubled to NZ$275.5m (34.3% of revenue, up from 18.1%), so company-defined free cash flow swung to -NZ$127.5m from +NZ$39.6m. Gross borrowings rose to NZ$243.2m from NZ$112.4m, taking net debt to NZ$172.7m from NZ$42.6m. The interim dividend was lifted 2.9% to NZ$0.18 per share.
What matters
- Tax-driven NPAT drag. The cleaner operating read is PBT +23.0%, not NPAT +11.9%. The entire 11pp growth gap is explained by the normalisation of the tax rate; there are no disclosed discontinued operations.
- Cash conversion deteriorated despite stronger earnings. FCF-to-NPAT fell to -118.8% from +41.3%. The swing is dominated by capex intensity rising to 34.3% of revenue, suggesting a step-up in infrastructure investment that is consuming the entire operating cash inflow and more.
- Leverage and payout tension. Net debt quadrupled, and the interim dividend alone represents 97.3% of HY24 NPAT and is not covered by free cash flow on either a pre- or post-lease basis. If capex remains at current intensity, the dividend is being funded from the balance sheet rather than from cash generation.
Expectations
No quantitative targets were disclosed. Management cited stable Hospital ordering and continued Homecare growth but gave no guidance. Against the FY23 anchor, HY23 represented only 43.7% of full-year revenue and 38.3% of full-year NPAT, so the business is structurally second-half weighted; applying that shape would imply a materially larger 2H24. Annualised HY24 revenue of NZ$1.61b already sits slightly above FY23's NZ$1.58b, indicating a modestly better run-rate, but the release does not support quantifying how much 2H24 upside is already embedded.
Quality of result
The earnings line looks genuine: revenue growth was 16% in both reported and constant currency, PBT grew faster than revenue, and inventory days fell from 105.0 to 81.6, indicating the prior-year inventory build is unwinding rather than being written off. That said, the cash quality is visibly weaker. Receivable days crept up to 42.9 from 40.6, operating cash flow is flattered by the unusually low NZ$1.9m HY23 base (FY23 as a whole generated only NZ$238.2m), and the NZ$275.5m capex spend is the single largest consumer of cash. Balance-sheet assistance — borrowings up NZ$130.8m — is what allowed dividends and capex to both be funded this half. None of the uplift looks timing- or accrual-driven, but the durability of the dividend at current capex intensity is not demonstrated here.
Unresolved
- What is the expected capex run-rate beyond HY24, and when does the step-up normalise?
- Why did the effective tax rate rise 7.6pp, and is 23.7% the new steady-state rate?
- Gross margin was not disclosed; given the Homecare mix shift and FX discussion, is underlying margin expanding, flat, or compressing?
- Is the company-defined "free cash flows+" measure reconciled to statutory lines elsewhere, and how should it be read against the dividend commitment?
- What portion of the Homecare growth is OSA masks versus new applications, and how sustainable is the 25.8% growth rate?
This briefing cannot assess gross-margin dynamics, segment profitability, or the durability of the elevated capex programme because none of those were disclosed in the supplied release.
Key metrics
| Metric | HY24 | HY23 | Change |
|---|---|---|---|
| Revenue | $803.7m | $690.6m | +16.4% ↑ |
| Net profit after tax | $107.3m | $95.9m | +11.9% ↑ |
| Net cash inflow from operating activities | $156.5m | $1900m | -91.8% ↓ |
| Interim dividend per share | 18.0c | 17.5c | +2.9% ↑ |
| Operating profit | $152.6m | $126.7m | +20.4% ↑ |
| Profit before tax | $140.6m | $114.3m | +23.0% ↑ |
| Total assets | $2389.8m | $2094.5m | +14.1% ↑ |
Reference: annolyse.ai/briefings/fph-hy24
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Hospital product group | $487.5m | $438.7m | — | -2.9pp |
| Homecare product group | $314.4m | $249.9m | — | +2.9pp |
Reference: annolyse.ai/briefings/fph-hy24
Analytical metrics
| Metric | HY24 | HY23 | Context |
|---|---|---|---|
| PBT growth | +23.0% | — | cleaner earnings measure |
| Effective tax rate | 23.7% | 16.1% | — |
| FCF pre-lease | −$119.0m | −$122.9m | +$3.9m |
| FCF post-lease | −$127.5m | $39.6m | −$167.1m |
| FCF / NPAT | -118.8% | 41.3% | complementary conversion metric |
| Capex % revenue | 34.3% | 18.1% | — |
| Capex | −$275.5m | $124.8m | −$400.3m |
| Free cash flow | −$127.5m | $39600.0m | −$39727.5m |
| Debtor days | 42.9 | 40.6 | +2.3 days |
| Inventory days | 81.6 | 105.0 | -23.4 days |
| Trade debtors | $189.2m | $153.8m | +$35.4m |
| Net debt | $172.7m | $42.6m | +$130.1m |
| Gross borrowings | $243.2m | $112.4m | +$130.8m |
| Payout ratio vs NPAT | 97.3% | — | — |
| Payout ratio vs FCF pre-lease | -88.1% | — | not covered |
| ROE (annualised) | 12.2% | 13.0% | Weakening |
| HY23 share of FY23 revenue | 43.7% | — | Other half was 56.3% |
| HY23 share of FY23 NPAT | 38.3% | — | Other half was 61.7% |
| Profit from continuing operations | $107.3m | $95.9m | +$11.4m |
Reference: annolyse.ai/briefings/fph-hy24
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.